6MWD	Six-minute walk distance
ACEi	Angiotensin-converting enzyme inhibitor
ARB	Angiotensin receptor blocker
ARNI	Angiotensin receptor–neprilysin inhibitor
CI	Confidence interval
CMR	Cardiac magnetic resonance
CV	Cardiovascular
eGFR	Estimated glomerular filtration rate
GRADE	Grading of Recommendations Assessment, Development, and Evaluation
HF	Heart failure
HFmrEF	Heart failure with mildly reduced ejection fraction
HFpEF	Heart failure with preserved ejection fraction
HFrEF	Heart failure with reduced ejection fraction
HR	Hazard ratio
I2	Inconsistency index
KCCQ	Kansas City Cardiomyopathy Questionnaire
KCCQ-CSS	Kansas City Cardiomyopathy Questionnaire—Clinical Summary Score
KCCQ-TSS	Kansas City Cardiomyopathy Questionnaire—Total Symptom Score
LV	Left ventricle/left ventricular
LVEDV	Left ventricular end-diastolic volume
LVEF	Left ventricular ejection fraction
LVESV	Left ventricular end-systolic volume
MD	Mean difference
NNT	Number needed to treat
NT-proBNP	N-terminal pro-B-type natriuretic peptide
NYHA	New York Heart Association
OR	Odds ratio
PCr/ATP	Phosphocreatine-to-adenosine triphosphate ratio
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PROSPERO	International Prospective Register of Systematic Reviews
RCT	Randomized controlled trial
RoB 2	Cochrane Risk of Bias 2 tool
RR	Risk ratio
SD	Standard deviation
SE	Standard error
SGLT2i	Sodium–glucose cotransporter-2 inhibitor
SMD	Standardized mean difference
T2DM	Type 2 diabetes mellitus
VE/VCO2	Ventilatory equivalent for carbon dioxide
VO2	Oxygen consumption
31P-MRS	Phosphorus-31 magnetic resonance spectroscopy